The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical therapeutic effects of neoadjuvant chemotherapy in resectable pancreatic cancer.
 
Masaaki Murakawa
No Relationships to Disclose
 
Daishi Takahashi
No Relationships to Disclose
 
Shinnosuke Kawahara
No Relationships to Disclose
 
Yuto Kamioka
No Relationships to Disclose
 
Naoto Yamamoto
No Relationships to Disclose
 
Shun Tezuka
No Relationships to Disclose
 
Satoshi Kobayashi
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Incyte; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); JPH Clinical Development (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Manabu Morimoto
No Relationships to Disclose
 
Takashi Oshima
No Relationships to Disclose
 
Norio Yukawa
No Relationships to Disclose
 
Yasushi Rino
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson; Lilly; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Research Funding - Abbott Nutrition (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Nihon Pharma (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tsumura & Co. (Inst)
 
Soichiro Morinaga
No Relationships to Disclose